May 8 |
Pharming reports Q1 results
|
May 8 |
Pharming GAAP EPS of -$0.01 misses by $0.02, revenue of $55.6M misses by $14.47M
|
May 8 |
Pharming Group reports first quarter 2024 financial results and provides business update
|
Apr 24 |
Pharming Group to report first quarter 2024 financial results on May 8
|
Apr 24 |
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
|
Apr 22 |
Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
|
Apr 19 |
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
|
Apr 18 |
Pharming Group announces the placement of €100 million convertible bonds due 2029
|
Apr 18 |
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
|
Apr 8 |
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
|